Hydralyte is the leading oral rehydration product in Australia and New Zealand.In April 2014, Prestige Brands Holdings, Inc. announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other over-the-counter healthcare products, for $750 million in cash.In November 2015, Prestige Brands Holdings, Inc. announced that it has entered into a definitive agreement to acquire DenTek Oral Care Inc. (DenTek), a privately-held marketer and distributor of oral care products for $225 million in cash.In December 2016, Prestige Brands Holdings, Inc. agreed to buy C.B. Fleet Co. from private-equity firm Gryphon Investors for about $825 million. Divestitures
In 2009, Prestige sold its Denorex and Prell brands of shampoo. It has since divested Fiber Choice, PediaCare, New-Skin, and Dermoplast (2016). Products
Prestige Brands owns many over-the counter medicines and products, including:

References
External links
Official website
Marketwatch - Prestige Brands Hldgs Inc.
Combined liver-kidney transplantation has been attempted in patients with aHUS, although this high-risk procedure has a mortality rate approaching 50%.Prior to availability and usage of the treatments,  quality of life was very poor for patients with aHUS; burdened with fatigue, renal complications, hypertension, neurological impairment, gastrointestinal distress, clotting at the site of venous access, and in worst cases, death. PE/PI is also reported to be associated with significant safety risks and is highly disruptive to patients lives due to the requirements for extensive vascular access and frequent administration.Since the approval of eculizumab (Soliris) the prognosis for aHUS patients has improved greatly. Risk of relapse is present after discontinuation of eculizumab treatment and close monitoring is required. Epidemiology
aHUS can be inherited or acquired, and does not appear to vary by race, gender, or geographic area. As expected with an ultra-rare disease, data on the prevalence of aHUS are extremely limited. A pediatric prevalence of 3.3 cases per million population is documented in one publication of a European hemolytic uremic syndrome (HUS) registry involving 167 pediatric patients. Society and culture
Naming
Atypical hemolytic uremic syndrome (aHUS) has also been referred to as diarrhea-negative hemolytic-uremic syndrome (D− HUS). : 2170

Research directions
Patient advocacy groups have been helping to determine research priorities. References


== External links ==